-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
CRISPR Therapeutics AG quarterly/annual Nonoperating Income (Expense) history and growth rate from 2014 to 2024.
- CRISPR Therapeutics AG Nonoperating Income (Expense) for the quarter ending December 31, 2024 was $28M, a 39.9% increase year-over-year.
- CRISPR Therapeutics AG Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $104M, a 44.7% increase year-over-year.
- CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2024 was $104M, a 44.7% increase from 2023.
- CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2023 was $71.8M, a 217% increase from 2022.
- CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2022 was $22.7M, a 277% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)